What Is Serina Therapeutics, Inc. (SER) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Serina Therapeutics, Inc.'s intrinsic value is estimated at $1.27. Trading at its current price of $1.95, the valuation engine raises significant caution: 8 of 9 models flag downside risk, projecting an average implied return of -34.9%. The most optimistic model, Dynamic NAV, places fair value at $2.13 (+9.2%), while ML-RIV — the most conservative — estimates $0.44 (-77.3%). This +86.5% gap reflects genuine analytical uncertainty about Serina Therapeutics, Inc.'s intrinsic worth.
What Do the Models Say About SER?
9 of 13 models are currently active for SER. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates SER's intrinsic value at $1.15, implying -40.9% downside from the current price. See which stocks rank higher →
How Does SER Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SER ranks #260 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Serina Therapeutics, Inc., metrics like revenue per drug provide important context that general-purpose valuation models may underweight.
Is SER a Value Trap?
CirclFi's Value Trap algorithm assigns SER a score of 54/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Serina Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Serina Therapeutics, Inc. earns a quality score of 4.6/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.
The gap between the most bullish and bearish model spans +86.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SER valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SER's 9 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad